GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Carmell Corp (NAS:CTCX) » Definitions » Debt-to-Revenue

Carmell (Carmell) Debt-to-Revenue : N/A (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Carmell Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Carmell's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.88 Mil. Carmell's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.67 Mil. Carmell's annualized Revenue for the quarter that ended in Mar. 2024 was $0.00 Mil.


Carmell Debt-to-Revenue Historical Data

The historical data trend for Carmell's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Carmell Debt-to-Revenue Chart

Carmell Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-Revenue
N/A N/A N/A

Carmell Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only N/A N/A 0.65 N/A N/A

Competitive Comparison of Carmell's Debt-to-Revenue

For the Household & Personal Products subindustry, Carmell's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Carmell's Debt-to-Revenue Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Carmell's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Carmell's Debt-to-Revenue falls into.



Carmell Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Carmell's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.439 + 0.698) / N/A
=N/A

Carmell's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.878 + 0.666) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Carmell Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Carmell's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Carmell (Carmell) Business Description

Traded in Other Exchanges
N/A
Address
2403 Sidney Street, Suite 300, Pittsburgh, PA, USA, 15203
Carmell Corp is a regenerative care company with a focus on using human biomaterials for aesthetic and medical care. Its commercial product is a human amnion allograft that can be used as a structural barrier for wound healing. Carmell's R&D pipeline includes several innovative aesthetic, epithelial and bone products under development.
Executives
David W Anderson director 519 LYNMERE ROAD, BRYN MAWR PA 19010
Kathryn Gregory director 305 THAYER POND ROAD, WILTON CT 06897
Patrick A Sturgeon officer: CFO and Secretary 600 LEXINGTON AVENUE 33 FLOOR, NEW YORK NY 10022
Richard A Upton director 12 MIDDLE STREET, AMHERST NH 03031
Rajiv Shukla director, 10 percent owner, officer: Chief Executive Officer EMERALD VIEW SUITE 400, 2054 VISTA PARKWAY, WEST PALM BEACH FL 33411
Randolph W Hubbell director, officer: President and CEO C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
William R Newlin director C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Steven Bariahtaris director C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Jaime Garza director C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Janet Vargo officer: VP Clinical Services C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Donna Godward officer: Chief Quality Officer C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
James C Hart officer: Chief Medical Officer C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
William Woodward director ANTHEM VENTURE PARTNERS, 225 ARIZONA AVENUE, SUITE 200, SANTA MONICA CA 90401
Darlene T Deremer director 200 CENTRAL AVENUE, SUITE 1850, ST. PETERSBURG FL 33701
Ahac Sponsor Iii Llc 10 percent owner 1177 AVENUE OF THE AMERICAS, 5TH FLOOR, NEW YORK NY 10036